Molecular MR imaging and MR-guided ultrasound therapies in cancer

JBR-BTR

Volumn 92, Issue 1, 2009, Pages 8-12

  Grenier, N ^a,b   Quesson, B ^a   De Senneville, B Denis ^a   Trillaud, H ^b,c   Couillaud, F ^a   Moonen, C ^a  

^a UMR 5287   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

MR neoplasms; Neoplasms; Therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; SCATTER FACTOR RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

APOPTOSIS; ARTICLE; ARTIFACT; BODY POSITION; CANCER CELL CULTURE; CELL LABELING; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; GLIOMA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMMUNOHISTOCHEMISTRY; MAGNETIC FIELD; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; THERMOMETRY;

CATHETER ABLATION; HUMANS; MAGNETIC RESONANCE IMAGING; MONITORING, INTRAOPERATIVE; NEOPLASMS; ULTRASONIC THERAPY; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 63849337209     PISSN: 17802393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Gilad A.A., et al.: Developing MR reporter genes: promises and pitfalls. NMR Biomed, 2007, 20: 275-90.
2. Cai W., Niu G., Chen X.: Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging, 2008, 35: 186-208.
3. Artemov D., et al.: MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med, 2003, 49: 403-408.
4. Funovics M.A., et al.: MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging, 2004, 22: 843-850.
5. Lee J.H., et al.: Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med, 2007, 13: 95-99.
6. Daldrup-Link H.E., et al.: In vivo tracking of genetically engineered, anti- HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol, 2005, 15: 4-13.
7. Towner R.A., et al.: In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging, 2007, 6: 18-29.
8. Wang X., et al.: A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell, 2002, 9: 411-421.
9. Towner R.A., et al.: In vivo detection of c-Met expression in a rat C6 glioma model. J Cell Mol Med, 2008, 12: 174- 186.
10. Knudsen B.S., et al.: A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol, 2009, 17: 57-67.
11. Weissleder R., et al.: In vivo magnetic resonance imaging of transgene expression. Nat Med, 2000, 6: 351-355.
12. Pirollo K.F., et al.: A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging, 2006, 5: 41-52.
13. Chang S.S.: Overview of prostatespecific membrane antigen. Rev Urol, 2004, 6 Suppl 10: S13-18.
14. Serda R.E., et al.: Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging, 2007, 6: 277-288.
15. McDonald D.M., Choyke RL: Imaging of angiogenesis: from microscope to clinic. Nat Med, 2003, 9: 713-725.
16. Neubauer A.M., et al.: Gadoliniummodulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med, 2008, 60: 1066-1072.
17. Schmieder A.H., et al.: Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med, 2005, 53: 621-627.
18. Burtea C., et al.: Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd- DTPA. Cardiovasc Res, 2008, 78: 148- 157.
19. Hakumaki J.M., Brindle K.M.: Techniques: Visualizing apoptosis using nuclear magnetic resonance. Trends Pharmacol Sci, 2003, 24: 146- 149.
20. Zhao, M., et al.: Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med, 2001, 7: 1241- 1244.
21. Krishnan A.S., et al.: Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology, 2008, 246: 854-862.
22. de Senneville B.D., et al.: MR thermometry for monitoring tumor ablation. Eur Radiol, 2007, 17: 2401-2410.
23. Quesson B., et al.: Automatic control of hyperthermic therapy based on real-time Fourier analysis of MR temperature maps. Magn Reson Med, 2002, 47: 1065-1072.
24. de Senneville B.D., Mougenot C., Moonen C.T.: Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med, 2007, 57: 319-330.
25. Maclair G., et al.: PCA-based magnetic field modeling: application for online MR temperature monitoring. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv, 2007, 10(Pt 2): 411-419.
26. McDannold N., et al.: Uterine leiomyomas: MR imaging-based thermometry and thermal dosimetry during focused ultrasound thermal ablation. Radiology, 2006, 240: 263-272.
27. Tempany C.M., et al.: MR imagingguided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology, 2003, 226: 897-905.
28. Gianfelice D., et al.: MR imagingguided focused US ablation of breast cancer: histopathologic assessment of effectiveness - initial experience. Radiology, 2003, 227: 849-855.
29. Wu F., ter Haar G., Chen W.R.: Highintensity focused ultrasound ablation of breast cancer. Expert Rev Anticancer Ther, 2007, 7: 823-831.
30. Hynynen K., Clement G.: Clinical applications of focused ultrasoundthe brain. Int J Hyperthermia, 2007, 23: 193-202.
31. Vykhodtseva N., McDannold N., Hynynen K.: Induction of apoptosis in vivo in the rabbit brain with focused ultrasound and Optison. Ultrasound Med Biol, 2006, 32: 1923-1929.
32. Palussiere J., et al.: Feasibility of MR- guided focused ultrasound with realtime temperature mapping and continuous sonication for ablation of VX2 carcinoma in rabbit thigh. Magn Reson Med, 2003, 49: 89-98.
33. Mougenot C., et al.:Three-dimensional spatial and temporal temperature control with MR thermometry-guided focused ultrasound (MRgHIFU). Magn Reson Med, 2008.
34. Rebillard X., et al.: Transrectal highintensity focused ultrasound in the treatment of localized prostate cancer. J Endourol, 2005, 19: 693-701.
35. Rebillard X., et al.: High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int, 2008, 101: 1205-1213.
36. Murat F.J., et al.: High-Intensity Focused Ultrasound (HIFU) for Prostate Cancer. Cancer Control, 2007, 14: 244-249.
37. Wharton I.P., et al.: Design and development of a prototype endocavitary probe for high-intensity focused ultrasound delivery with integrated magnetic resonance imaging. J Magn Reson Imaging, 2007, 25: 548-556.
38. Pisani L.J., et al.: Effects of spatial and temporal resolution for MR imageguided thermal ablation of prostate with transurethral ultrasound. J Magn Reson Imaging, 2005, 22: 109- 118.
39. Wu F., et al.: A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br J Cancer, 2003, 89: 2227-2233.
40. Furusawa H., et al.:The evolving nonsurgical ablation of breast cancer: MR guided focused ultrasound (MRgFUS). Breast Cancer, 2007, 14: 55-58.
41. Zippel D.B., Papa M.Z.:The use of MR imaging guided focused ultrasound in breast cancer patients; a preliminary phase one study and review. Breast Cancer, 2005, 12: 32-38.